Welcome to our July research update! Getting involved with research is an important way to impact asthma and allergy treatments, education, and awareness.
This month, we are highlighting clinical trials, interviews, focus groups, and news on:
- Asthma
- RSV treatment
- Atopic dermatitis treatment
- Slowing the atopic march
- Oral immunotherapy for multiple food allergens
- Skin stamp for peanut allergy
Asthma and Allergy Clinical Trials
Are You Currently Taking Oral Corticosteroids (OCS) for Your Asthma?
Would you like to contribute to important new research? SUNRISE is a clinical study investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for OCS in adults with severe asthma. The study is looking for people who:
- Are between 18 and 80 years of age
- Have had an asthma diagnosis for at least 1 year
- Have been taking OCS for asthma for at least 6 months
- Have been using inhaled corticosteroids for at least a year, and a long-acting beta 2-agonist (LABA) for at least 3 months
- Have not been receiving any biologic treatment for asthma for at least 4 months
Sponsored by AstraZeneca
Interviews and Focus Groups
Participants Needed for Adolescent Asthma Self-Management Study
Researchers at Texas Woman’s University want to learn more about adolescent asthma self-management. The researchers would like to understand the experiences and perspectives of adolescents living with asthma. Adolescents will have a chance to speak about their asthma control, asthma tools, and experiences. The study format will be a private interview. Interviews will take place via Zoom.
Who may qualify to participate in this study?
- Adolescents living with asthma
- 12-21 years old
- English speaker
The study participants will be given:
- $20 Amazon gift card
- Asthma resources
Participation is voluntary. You can stop the sessions at any time. There is a potential risk for loss of confidentiality in all email downloading, electronic meetings, and internet transactions. If you have further questions about the study, please call Elif Isik (PhD, RN) at (713) 794-2109 or email her at eisik@twu.edu.
Participants Needed for Mild Asthma Focus Group
Researchers at the University of Michigan are hoping to learn more about mild asthma. The researchers would like to better understand patients’ experiences with, and concerns about, mild asthma to direct future areas of research.
Participation will include a Qualtrics survey with demographic and asthma control questions, and participation in a 1.5-2.5-hour focus group conducted over Zoom. The focus groups will be recorded such that responses can be transcribed for data analysis.
Who may qualify to participate?
- Patients 18 years or older with mild/intermittent asthma
- Parents of children with mild/intermittent asthma
If you are eligible and selected to participate, you will receive $100 compensation for completion of a Qualtrics survey, and focus group conducted over Zoom.
Participation is voluntary and you can stop participating at any time.
Please click below to proceed to a survey for eligibility screening.
Latest Asthma and Allergy Research News
Asthma
PCORI Grants Award to Study Individualizing Treatment for Asthma in Primary Care
The Patient-Centered Outcomes Research Institute (PCORI) has granted an award for a new study looking at individualized treatment for asthma in primary care. The study will enroll 3,200 people with asthma and assign them to one of four groups. Each of these groups will receive different treatments for their asthma. The main goal of the study is to compare the yearly rates of asthma flare-ups among the different treatment groups. The study will also look at asthma control and quality of life. The results of the study will help doctors and patients determine the most suitable treatment based on individual characteristics. Insurers can also use the findings to make decisions about which therapies to cover. Stakeholders from different groups, including AAFA, are actively involved in shaping the research questions and study design.
Atopic Dermatitis
Possible New Treatment for Atopic Dermatitis Shows Positive Results in Phase 2 of Clinical Trial
New study results from Sanofi show positive results for a possible new treatment for atopic dermatitis. A phase 2 clinical trial was conducted to test the treatment (amlitelimab) in adults with moderate-to-severe atopic dermatitis. The results show participants who took amlitelimab showed significant improvements in their condition compared to a placebo. The improvements were seen in different doses of the medicine, and the positive effects continued for up to 24 weeks. The study also found that the treatment was well-tolerated and did not cause any new safety concerns. The results suggest that amlitelimab may be a promising option for people with atopic dermatitis who have not responded well to other treatments.
Dupilumab Effective in Reducing New Allergies and Slowing Atopic March Food Allergy
A new study looks at the effectiveness of dupilumab in reducing the development of new allergies or the worsening of existing allergies in people with atopic dermatitis. The researchers analyzed data from 12 clinical trials involving 3,525 patients with moderate-to-severe atopic dermatitis. The results showed that people treated with dupilumab had a 34% reduction in new or worsened allergies and a 37% reduction in new allergies. The study suggests that dupilumab may be effective in reducing the atopic march, especially in younger patients with early-onset atopic dermatitis and more severe symptoms. Longer studies are needed to confirm these findings, but the results show promise in treating allergies associated with atopic dermatitis.
Food Allergy
New Study Shows Racial, Ethnic, and Socioeconomic Differences in Food Allergies in the United States
A new study highlights the estimated prevalence of food allergy across racial, ethnic, and socioeconomic groups in the United States. Researchers conducted a nationally representative survey of more than 50,000 households. The results show that Asian, Black, and Hispanic people were more likely to report having food allergies compared with white people. The rate of food allergies was lowest among households in the highest income bracket. More research is needed to understand how socioeconomic factors and environmental factors may relate to food allergy in order to inform treatment and interventions and reduce food allergy disparities.
Moonlight Therapeutics Receives Clinical Trial Grant to Evaluate MOON101 Skin Stamp for Peanut Allergy
Moonlight Therapeutics, a biotechnology company, has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to test their new treatment called MOON101. MOON101 is designed for peanut allergy in children and adults. The treatment uses a special skin stamp to deliver small amounts of allergens to the skin and help desensitize people with food allergies. The stamp is designed to be used at home and only needs to be applied for a few minutes. The clinical trial will be conducted with leading food allergy centers in the United States, and will help Moonlight Therapeutics continue to study the effects of the treatment on people with food allergy.
Oral Immunotherapy (OIT) for Multiple Food Allergens Shows Positive Results in Early Clinical Trial
Alladapt Immunotherapeutics, Inc. has announced positive results from the Harmony study. The study tested the effectiveness and safety of their treatment (ADP101) for single and multiple food allergies. ADP101 is an oral immunotherapy designed to desensitize patients with common food allergies. The study showed that ADP101 had meaningful effects on patients, with higher doses showing better results. The treatment was generally well-tolerated with minimal side effects. The company plans to continue developing ADP101 in partnership with the food allergy community, with the goal of seeking regulatory approval for treatment use.
Respiratory Syncytial Virus (RSV)
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
The Food and Drug Administration (FDA) has approved a treatment called Beyfortus (nirsevimab-alip) to prevent respiratory syncytial virus (RSV) in newborns, infants, and young children. RSV is a virus that causes respiratory infections. It can be very severe in babies and young children. Beyfortus is a type of treatment called a monoclonal antibody that helps fight against RSV. It is given as a single injection before or during the RSV season to provide protection. Previous clinical trials on the treatment showed a significant reduction in RSV infections. Possible side effects include rash and injection site reactions. The approval of Beyfortus provides a new option to help reduce the impact of RSV on children and their families.
It is important to stay up to date on news about asthma and allergies. By joining our community and following our blog, you will receive news about research and treatments. Our community also provides an opportunity to connect with other people who manage these conditions for support.
Comments (0)